Liposcience Inc (LPDX) 5.24 $LPDX
Miraculins: Pioneering a New Approach to Diabetes Screening
ACCESSWIRE - Tue Jan 27, 7:03AM CST
WINNIPEG, CA / ACCESSWIRE / January 27, 2015 / Diabetes affects nearly 30 million U.S. citizens - or roughly 10% of the population - with about 27% of those cases going undiagnosed, according to the American Diabetes Association. As well, there are approximately 80 million Americans estimated to be pre-diabetic, with 90% being completely unaware of their condition. With about 70,000 deaths in 2010 alone, diabetes is the seventh leading cause of death in the U.S. and that figure could be dramatically understated given the chronic under-diagnosis of the disease. [1] As well, diabetes and its related complications accounted for $245 billion USD in total medical costs and lost work and wages in the U.S. in 2012.[2] More than 500 million people worldwide are expected to be affected by diabetes by the year 2030, making it the 7th leading cause of death in the world. [3] [4]
LPDX: 5.24 (-0.01), MOM.VN: 0.210 (+0.005), HITK: 43.49 (-0.01)
Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 285.37 (+3.71), MONT: 22.59 (+0.26), CHYR: 2.81 (+0.01), TDY: 100.91 (+1.11), QRE: 14.35 (-0.50), HAL: 44.19 (+1.42), BBEP: 7.85 (+0.32), AGN: 229.49 (+1.87), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.72 (+0.12), BNCN: 16.66 (-0.04), LH: 116.90 (+0.06), OPLK: 24.23 (-0.03), BHI: 64.31 (+1.93)
LabCorp Completes Acquisition of LIPOSCIENCE
Business Wire - Fri Nov 21, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014.
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LipoScience net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:02AM CST
LPDX: 5.24 (-0.01)
LipoScience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:32AM CST
LPDX: 5.24 (-0.01)
LipoScience Announces 2014 Third Quarter Financial Results
GlobeNewswire - Wed Nov 12, 6:00AM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced its financial results for the third quarter ended September 30, 2014.
LPDX: 5.24 (-0.01)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 14.92 (+0.93), ATHL: 58.40 (unch), VIPS: 21.80 (+0.36), ARII: 54.26 (-0.46), SBAC: 121.67 (+2.01), BIOF: 7.28 (+0.01), BKW: 35.50 (-1.16), LUV: 43.30 (-0.20), HCA: 68.54 (-0.48), LPDX: 5.24 (-0.01), DTV: 87.51 (-0.32), RCPT: 115.83 (-0.66), WMB: 49.41 (+1.44), BRK.B: 148.34 (-1.45), BRK.A: 222,555.00 (-1,905.00), SBGL: 10.85 (+0.12), AN: 63.70 (+0.23)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of LipoScience, Inc. of Class Action Against the Board of Directors of the Company Challenging the Fairness of the Sale of the Company to LabCorp -- LPDX
GlobeNewswire - Mon Oct 20, 9:33AM CDT
Levi & Korsinsky notifies investors of LipoScience Inc. ("LipoScience" or "the Company"
(Nasdaq:LPDX) of claims breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to LabCorp. A complaint was filed in North Carolina state court.
LPDX: 5.24 (-0.01)
LipoScience announces Antitrust Approval for pending acquisition by LabCorp
M2 - Thu Oct 16, 10:00AM CDT
Diagnostic tests company LipoScience (NasdaqGM:LPDX) reported on Wednesday that it has received the Federal Trade Commission's early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to its acquisition by Laboratory Corporation of America Holdings (LabCorp) (NYSE:LH).
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LabCorp's Acquisition of LipoScience Clears Antitrust Approval
Business Wire - Wed Oct 15, 6:15PM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (NASDAQ: LPDX) by LabCorp.
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LIPOSCIENCE SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by LabCorp
Business Wire - Wed Oct 15, 2:55PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience" (NasdaqGM: LPDX) concerning the acquisition by Laboratory Corporation of America Holdings. Under the terms of the agreement, valued at approximately $85 million, LipoScience shareholders will only receive $5.25 in cash per share owned.
LPDX: 5.24 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection with the Sale of the Company
Business Wire - Tue Oct 14, 5:32PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience" or the "Company" (Nasdaq: LPDX) relating to the proposed acquisition by Laboratory Corporation of America Holdings ("LH" .
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of LipoScience, Inc. in Connection With the Sale of the Company to LabCorp - LPDX
Business Wire - Tue Oct 14, 11:36AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of LipoScience Inc. (Nasdaq:LPDX) ("LipoScience" in connection with the sale of the Company to LabCorp.
LPDX: 5.24 (-0.01)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 7.29 (-0.06), ATHL: 58.40 (unch), LPDX: 5.24 (-0.01), TIBX: 24.03 (+0.03), AMBI: 15.60 (+0.26), SMPL: 17.70 (+0.20)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection with the Sale of the Company -LPDX
PR Newswire - Sat Oct 04, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience" or the "Company" (Nasdaq -LPDX-News) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LH" .
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of LipoScience, Inc. Concerning the Fairness of the Sale of the Company to LabCorp
Business Wire - Thu Oct 02, 11:25AM CDT
Levi & Korsinsky is investigating the Board of Directors of LipoScience Inc. ("LipoScience" or "the Company" (NASDAQ:LPDX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to LabCorp.
LPDX: 5.24 (-0.01)
Miraculins: Pioneering a New Approach to Diabetes Screening
ACCESSWIRE - Tue Jan 27, 7:03AM CST
WINNIPEG, CA / ACCESSWIRE / January 27, 2015 / Diabetes affects nearly 30 million U.S. citizens - or roughly 10% of the population - with about 27% of those cases going undiagnosed, according to the American Diabetes Association. As well, there are approximately 80 million Americans estimated to be pre-diabetic, with 90% being completely unaware of their condition. With about 70,000 deaths in 2010 alone, diabetes is the seventh leading cause of death in the U.S. and that figure could be dramatically understated given the chronic under-diagnosis of the disease. [1] As well, diabetes and its related complications accounted for $245 billion USD in total medical costs and lost work and wages in the U.S. in 2012.[2] More than 500 million people worldwide are expected to be affected by diabetes by the year 2030, making it the 7th leading cause of death in the world. [3] [4]
LPDX: 5.24 (-0.01), MOM.VN: 0.210 (+0.005), HITK: 43.49 (-0.01)
Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 285.37 (+3.71), MONT: 22.59 (+0.26), CHYR: 2.81 (+0.01), TDY: 100.91 (+1.11), QRE: 14.35 (-0.50), HAL: 44.19 (+1.42), BBEP: 7.85 (+0.32), AGN: 229.49 (+1.87), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.72 (+0.12), BNCN: 16.66 (-0.04), LH: 116.90 (+0.06), OPLK: 24.23 (-0.03), BHI: 64.31 (+1.93)
LabCorp Completes Acquisition of LIPOSCIENCE
Business Wire - Fri Nov 21, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014.
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LipoScience net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:02AM CST
LPDX: 5.24 (-0.01)
LipoScience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:32AM CST
LPDX: 5.24 (-0.01)
LipoScience Announces 2014 Third Quarter Financial Results
GlobeNewswire - Wed Nov 12, 6:00AM CST
LipoScience, Inc. (Nasdaq:LPDX) today announced its financial results for the third quarter ended September 30, 2014.
LPDX: 5.24 (-0.01)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 14.92 (+0.93), ATHL: 58.40 (unch), VIPS: 21.80 (+0.36), ARII: 54.26 (-0.46), SBAC: 121.67 (+2.01), BIOF: 7.28 (+0.01), BKW: 35.50 (-1.16), LUV: 43.30 (-0.20), HCA: 68.54 (-0.48), LPDX: 5.24 (-0.01), DTV: 87.51 (-0.32), RCPT: 115.83 (-0.66), WMB: 49.41 (+1.44), BRK.B: 148.34 (-1.45), BRK.A: 222,555.00 (-1,905.00), SBGL: 10.85 (+0.12), AN: 63.70 (+0.23)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of LipoScience, Inc. of Class Action Against the Board of Directors of the Company Challenging the Fairness of the Sale of the Company to LabCorp -- LPDX
GlobeNewswire - Mon Oct 20, 9:33AM CDT
Levi & Korsinsky notifies investors of LipoScience Inc. ("LipoScience" or "the Company"
(Nasdaq:LPDX) of claims breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to LabCorp. A complaint was filed in North Carolina state court. LPDX: 5.24 (-0.01)
LipoScience announces Antitrust Approval for pending acquisition by LabCorp
M2 - Thu Oct 16, 10:00AM CDT
Diagnostic tests company LipoScience (NasdaqGM:LPDX) reported on Wednesday that it has received the Federal Trade Commission's early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to its acquisition by Laboratory Corporation of America Holdings (LabCorp) (NYSE:LH).
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LabCorp's Acquisition of LipoScience Clears Antitrust Approval
Business Wire - Wed Oct 15, 6:15PM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (NASDAQ: LPDX) by LabCorp.
LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
LIPOSCIENCE SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by LabCorp
Business Wire - Wed Oct 15, 2:55PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience"
(NasdaqGM: LPDX) concerning the acquisition by Laboratory Corporation of America Holdings. Under the terms of the agreement, valued at approximately $85 million, LipoScience shareholders will only receive $5.25 in cash per share owned. LPDX: 5.24 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection with the Sale of the Company
Business Wire - Tue Oct 14, 5:32PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience" or the "Company"
(Nasdaq: LPDX) relating to the proposed acquisition by Laboratory Corporation of America Holdings ("LH" . LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of LipoScience, Inc. in Connection With the Sale of the Company to LabCorp - LPDX
Business Wire - Tue Oct 14, 11:36AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of LipoScience Inc. (Nasdaq:LPDX) ("LipoScience"
in connection with the sale of the Company to LabCorp. LPDX: 5.24 (-0.01)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 7.29 (-0.06), ATHL: 58.40 (unch), LPDX: 5.24 (-0.01), TIBX: 24.03 (+0.03), AMBI: 15.60 (+0.26), SMPL: 17.70 (+0.20)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection with the Sale of the Company -LPDX
PR Newswire - Sat Oct 04, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience" or the "Company"
(Nasdaq -LPDX-News) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LH" . LPDX: 5.24 (-0.01), LH: 116.90 (+0.06)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of LipoScience, Inc. Concerning the Fairness of the Sale of the Company to LabCorp
Business Wire - Thu Oct 02, 11:25AM CDT
Levi & Korsinsky is investigating the Board of Directors of LipoScience Inc. ("LipoScience" or "the Company"
(NASDAQ:LPDX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to LabCorp. LPDX: 5.24 (-0.01)
